7. Merck - Top 15 R&D Budgets

Who: Merck

2006 Pipeline Budget: $5.3 billion (€3.62)

2007 Pipeline News: One of Merck's biggest pipeline hopes is anacetrapib, a drug designed to increase good cholesterol and decrease bad cholesterol. Sound familiar? That's because anacetrapib is a CTEP inhibitor--the same class of drug as Pfizer's failed torcetrapib. The drug, which is currently in Phase II, could tap into a $15 billion market.

In 2007 Merck received FDA approval of HIV drug Isentress, filed an NDA for Cordaptive (a cholesterol drug that combines a known ingredient with a new one that reduces the risk of flushing). The company also inked a billion-dollar pact for Ariad's cancer drug AP23573, which is in late-stage testing for metastatic sarcomas. And Sanofi-Aventis better get its act together with Acomplia, because Merck's obesity drug taranabant is in Phase III and could be up for FDA approval in 2008.

Pending Approval:
MK-0518 (raltegravir) - HIV
MK-0517 - chemotherapy-induced nausea and vomiting (approvable)

Phase III
MK-0524A - Atherosclerosis
MK-0524B - Atherosclerosis
MK-0364 (taranabant) - Obesity
MK-0974 - Migraine
MK-8669 - Cancer

Full Pipeline Site: Link

7. Merck - Top 15 R&D Budgets

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.